Early diagnosis of non-alcoholic fatty liver disease: the role of biomarkers and complex indices of non-alcoholic fatty liver steatosis
-
Published:2023-10-09
Issue:8
Volume:
Page:27-36
-
ISSN:1682-8658
-
Container-title:Experimental and Clinical Gastroenterology
-
language:
-
Short-container-title:jour
Author:
Tarasova L. V.1ORCID, Tsyganova Yu. V.1ORCID
Affiliation:
1. Chuvash State University n. a. I. N. Ulyanov
Abstract
Metabolic syndrome is a series of pathologies united by a similar pathogenesis, the end of which, most often, is cardiovascular accidents, which are leaders among the causes of death in the population around the world. Non-alcoholic fatty liver disease (NAFLD) is the hepatic equivalent of the metabolic syndrome, registered earlier than all other equivalents, on the rights of the liver as a first-line energy depot. At the same time, according to multicenter studies, 95% of people with NAFLD (any stage) are not diagnosed with the disease. Clarification of additional risk factors for NAFLD and the presence of a specific biomarker of non-alcoholic liver steatosis would make it possible to stop the vicious cascade of metabolic processes, which in the future can lead to a significant increase in the life expectancy of the population. The potentially high role of Secreted Frizzled Related Protein-4 (SFRP4) adipokine in the early diagnosis of NAFLD is known. The aim of the study was to optimize the early diagnosis of non-alcoholic fatty liver disease using modern indices and biomarkers. Materials and methods. The work was carried out at the Department of Faculty and Hospital Therapy of the Chuvash State University named after I. N. Ulyanov” in the period from 2016 to 2020. This study included several stages: first of all, a retrospective analysis of 1150 outpatient records of patients from several medical organizations of the Chuvash Republic for the period 2016-2018 was carried out. to form two study groups: experimental and control. At the second stage, as a result of applying the exclusion criteria, 162 people remained in the experiment: 110 from the experimental group, 52 from the control group. The subjects of both groups were compared by gender and age, the age range of the subjects varied from 18 to 80 years old with an average value of 48.3 years. Further, the patients undergo a detailed examination, according to the presented plan: Collection of complaints, medical history, objective examination. Laboratory studies (general and biochemical blood tests, lipidogram, assessment of the level of serum adipokine SFRP4). Instrumental studies (ultrasound of the OBP, TE (SAR), ESP with elastometry). Evaluation of the most informative complex indices for the early diagnosis of NAFLD: MI, IVO indices, HSI, FLD-I. Further, all the necessary statistical processing and analysis of the obtained data were performed (Microsoft Office Excel 2016, StatTech v. 2.8.8 (developer - Stattech LLC, Russia)). Results. Accessible (not requiring the use of additional time and material costs) NAFLD indices with the highest sensitivity rates (99.1% and 98.2%, respectively) were MI and IVO. A noticeable direct correlation was traced between MI (p=0.640), moderate - between the IVO (p=0.398) and the elastographically determined index of non-alcoholic liver steatosis. High sensitivity and specificity of skin manifestations (xanthoma, xanthelasma - 69.6% and 89.7% and seborrheic dermatitis - 82.0% and 71.4%) were found in relation to early manifestations of NAFLD. From anthropometric indicators: the CW/CF index has a pronounced (ρ=0.643), CW - moderate (ρ=0.238), and BMI - a weak direct (ρ=0.223) correlation with the elastographically determined index of non-alcoholic liver steatosis. Adipokine SFRP4 correlates (ρ=0.841) with early manifestations of hepatic steatosis in patients, as determined by TE in CAP mode.
Publisher
LLC Global Media Technology
Subject
Gastroenterology,Hepatology
Reference49 articles.
1. Younossi Z.M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. 2. Kim N.H, Park J., Kim S. H., Kim Y. H., Kim D. H., Cho G. Y., Baik I., Lim H. E., Kim E. J., Na J. O., Lee J. B., Lee S. K., Shin C. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart. 2014; 100: 938-943. 3. Babenko A. Yu., Laevskaya M. Yu. Non-alcoholic fatty liver disease - relationship with metabolic syndrome. RMJ. 2018; 1(I): 34-40. (in Russ.)@@ Babenko A. Yu., Laevskaya M. Yu. Nealkogol'naya zhirovaya bolezn' pecheni - vzaimosvyazi s metabolicheskim sindromom. RMZh. 2018; 1 (I): 34-40. 4. Itskova E. A., Kryuchkova O. N., Lutai Yu. A., et al. The main provisions of the National clinical guidelines for the diagnosis, treatment, prevention of obesity and associated diseases. Crimean therapeutic journal. 2018; 4:5-11. (in Russ.)@@ Itskova E. A., Kryuchkova O. N., Lutai Yu. A. i dr. Osnovnye polozheniya Natsional'nykh klinicheskikh rekomendatsii po diagnostike, lecheniyu, profilaktike ozhireniya i assotsiirovannykh s nim zabolevanii. Krymskii terapevticheskii zhurnal. 2018; 4: 5-11. 5. Maev I. V., Tsukanov V. V., Lukicheva E. V. et al. Prevalence, pathogenesis and principles of treatment of non-alcoholic fatty liver disease. Pharmateka. 2011; 12(225): 12-15. (in Russ.)@@ Maev I. V., Tsukanov V. V., Lukicheva E. V. i dr. Rasprostranennost', patogenez i printsipy lecheniya nealkogol'noi zhirovoi bolezni pecheni. Farmateka. 2011; 12(225): 12-15.
|
|